stream
She is responsible for the chemistry, manufacturing and control operations of small molecules and biologics encompassing process development, production, supply chain management, analytical operations, laboratory information and quality assurance for Gilead’s investigational and commercial products.
Charles recently retired from a successful career at Bristol Myers Squibb where he held a number of leadership roles in commercial, strategy and finance. Together with a talented core team, Dr. Perlroth has built Kodiak on a foundation of scientific excellence with a simple mission—to design and develop important new medicines for highly prevalent diseases. Kodiak Sciences Appoints Taiyin Yang, Ph.D., to Board of Directors PR Newswire PALO ALTO, Calif., Dec. 19, 2019 PALO ALTO, Calif., Dec. 19, 2019 /PRNewswire/ -- Kodiak Sciences Inc…
/O 7
Mr. Profusek also currently serves as the lead independent director of both CTS Corporation (NYSE: CTS), a designer and manufacturer of sensors, actuators and electronic components, and Valero Energy Corporation (NYSE: VLO), an international manufacturer and marketer of transportation fuels and other petrochemical products.
0000002840 00000 n
He has led Xencor in raising over $700 million in public and private financing, creating a diverse portfolio of monoclonal antibody clinical programs for the treatment of life-threatening and debilitating diseases and establishing alliances with leading biopharmaceutical companies that generated over $200 million in upfront payments. endobj
PALO ALTO, Calif., April 2, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of directors. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Dr. Levy served at Sandoz, a pharmaceutical company and predecessor of Novartis, from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. He received his bachelor's degree in accounting from Charlie served as a member of the board of Colgate-Palmolive Company from 2017 to "Charlie joins our board as Kodiak accelerates its research and development activities and begins pre-commercial planning for KSI-301," said "I am thrilled to join Kodiak's board of directors. << endobj
Press Release Kodiak Sciences Appoints Charles Bancroft to Board of Directors Published: April 2, 2020 at 5:08 p.m.
/Filter /FlateDecode /Type /Page She received her bachelor’s degree in Chemistry from National Taiwan University and her PhD in Organic Chemistry from the University of Southern California.Some of the statements on this site are forward-looking. /Pages 2 0 R /Parent 2 0 R He received his A.B. /Subtype /Image Dr. Perlroth earned his M.D. /S /Transparency /Fit] >> x���}LUe�Ͻ ���T�Q3��d�h ĥ����n4�7�x�䏧O�(i��t��H��֔veZQѡx���Ѯ-�g��6����vߠ���'�$�L�Z��"3��j/]�W��r���>���?�e��T�ϓ���-����TFB8#P��~@`�|k�s;H�v�F���i���ZT���+z��e�F/�����_�[d�_��ؙ5T{�77�VT�*7X���h����ۗ���;��ϗ��ڪ������/�za������J
�%o�u{0��������IU����E���F�~~���7;�f�Z�i�u拉�ܟ��k23�L����m鶠w}�n��kN�3睠_ �R*����2�l�����e�8�í�ն���ɏ^��}��y��3�w�����*�5Ϲ�n̵4�ss���N�.Su":�Vx5��⬅����h��m��:���L{l�C��׆7ceh�͔*3�D3.�9q��z:7�~*�R��zd~�2����_��_,J��y��4����"�>O�����ps6=�l�H}2CW�2��h��
>> /Contents [12 0 R]
/Length 41 PALO ALTO, Calif., April 2, 2020 /PRNewswire/ -- Kodiak Sciences Inc (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of directors.
